The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Mitochondria

NAD+ + MOTS-C + 5-Amino-1MQ Blend

A 3-way anti-aging stack: NAD+, MOTS-c and 5-Amino-1MQ, three different metabolic approaches in one vial.

2 min read 12 sources

To the product To the calculator
Vial with white powder, a blue cap and a black TPD label for the blend of NAD+, MOTS-c and 5-Amino-1MQ on a white podium, next to it three different molecule models of blue glass spheres in a bright lab
Preclinical · not approvedLab tested in the shop

Summary

At a glance

Sources checked on 26 Oct 2026

Trials of the blend in the registry
0 trials

no trial with this combination on ClinicalTrials.gov, as of 26 Oct 202610

Length of MOTS-c
16 amino acids

encoded in mitochondrial DNA, described in 20153

Body weight with 5-amino-1MQ
-5.1 %

obese mice, 11 days, control group +1.4%, same food intake4

NAD+ without rise in plasma
2 hours

for that long NAD+ given as an infusion vanished from the blood at once, human pilot study6

Phase 1 with a MOTS-c analogue
88 people

modified form CB4211, healthy adults and fatty liver, results not posted in the registry5

  • The blend combines three compounds with different approaches to energy metabolism: the coenzyme NAD+, the mitochondrial peptide MOTS-c and the NNMT inhibitor 5-amino-1MQ.234
  • There is no study on the blend itself. All figures here come from studies on single components and are labelled as such.10
  • MOTS-c is a peptide of 16 amino acids from mitochondrial DNA. In mice it prevented age-related insulin resistance and insulin resistance caused by a high-fat diet.3
  • 5-Amino-1MQ inhibits the enzyme NNMT. Obese mice lost about 5 percent of their weight with it in 11 days on the same food intake. It has not been studied in humans.4
  • NAD+ has only been studied in humans as an infusion. None of the three components is approved. Everything here is the state of research, not a recommendation.61110
Profile

Updated May 2026

Class
Anti-aging/metabolic blend
Use
Subcutaneous

in mg

Contents
100 mg NAD+

10 mg MOTS-c, 10 mg 5-Amino-1MQ (120 mg)

Status
Components well described

blend experimental

Sizes
120 mg

1 size in the shop

Contents 15 sections
  1. At a glance
  2. What is this blend?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Dosing
  7. Injection
  8. What the research shows
  9. Research status
  10. Side effects
  11. Storage
  12. Related compounds
  13. FAQ
  14. Glossary
  15. Sources

What is this blend?

This blend combines three metabolic compounds from the anti-aging corner: NAD+ (a coenzyme of energy metabolism), MOTS-c (a mitochondrial peptide) and 5-Amino-1MQ (an NNMT inhibitor). You also find NAD+ and MOTS-c individually in the lexicon. The idea: three different levers of energy metabolism in one vial.

Comparison

Three approaches in one blend

The blend and its components in the TPD lexicon. Tap a card to open its entry.

Blend of three compounds NAD+ + MOTS-C + 5-Amino-1MQ Blend NAD+ AMPK NNMT 3 of 3 targets
Coenzyme NAD+ NAD+ AMPK NNMT 1 of 3 targets Mitochondrial peptide MOTS-c NAD+ AMPK NNMT 1 of 3 targets NNMT inhibitor 5-Amino-1MQ NAD+ AMPK NNMT 1 of 3 targets Tablets with 5-amino-1MQ and an NAD+ building block 5-Amino + NAD+ (Oral) NAD+ AMPK NNMT 2 of 3 targets

Whether the three compounds act differently together than alone has not been studied. 234

How it works

NAD+ powers the mitochondria and repair enzymes. MOTS-c acts as a mitochondrial signaling peptide on energy metabolism. 5-Amino-1MQ inhibits the enzyme NNMT, which is theorized to boost metabolism. All three target better mitochondrial and metabolic function, via different routes.

The individual mechanisms are in the lexicon entries for NAD+ and MOTS-c.

Where it acts

Where the components acted in studies

Tap a point or a card. Every finding comes from a single component, not from the blend.

  1. Skeletal muscle (MOTS-c)

    Main target of MOTS-c, AMPK activated, insulin resistance prevented (mice)3

    AMPK
  2. Fat tissue (5-amino-1MQ)

    Less fat tissue and smaller fat cells in obese mice4

    NNMT
  3. Heart (NAD+)

    Pump function higher after NAD+ infusion than on placebo (heart failure)7

    Observed in trials
  4. Blood plasma (NAD+)

    Infused NAD+ vanished from plasma at once for 2 hours6

    Observed in trials

Targets in the ChEMBL database12

Three recorded mechanisms, type of action on each card.

Sirtuin 1 (consumes NAD+)
Gene
SIRT1
UniProt
Q96EB6
ChEMBL
CHEMBL4506
Action
Needs NAD+ as a cosubstrate, component NAD+
AMPK, subunit alpha-1
Gene
PRKAA1
UniProt
Q13131
ChEMBL
CHEMBL4045
Action
Activated indirectly via the folate cycle, component MOTS-c
Nicotinamide N-methyltransferase
Gene
NNMT
UniProt
P40261
ChEMBL
CHEMBL2346486
Action
Inhibited, component 5-amino-1MQ, in cell assays
Translucent glass cell with several glowing mitochondria, three different blue molecules sending streams of light into it from outside
Three components target mitochondria and energy metabolism through different routes. Symbolic image.

What you need

Supplies

2 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Blend vial with a black TPD label reading “NAD+ + MOTS-C + 5-Amino-1MQ Blend” and a vial of bacteriostatic water at the same size, next to them two insulin syringes with blue caps, two alcohol swabs and a sharps container with a blue lid

  1. Blend vial

    The blend vial (lyophilized powder, three compounds).

    In the shop

  2. Water and supplies

    Bacteriostatic water, U-100 insulin syringes, alcohol swabs.

    In the shop

Reconstitution

Use the peptide calculator. The values refer to the total amount (120mg). A 120mg vial with 3ml water gives 40mg per ml. Just add the water to the vial and let it dissolve. NAD+ can trigger a flush feeling when injected, so go slow.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 120 mg + 3 ml = 40 mg/ml

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

Injection

The injection is subcutaneous, into the fat layer under the skin. Common spots are the abdomen (keep about two finger-widths clear of the navel), the front and the inner side of the thigh, or the back of the upper arm.

The short version:

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the spot with an alcohol swab and let it dry

  2. Pinch up a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject slowly, wait a moment, then withdraw

  5. Put the needle straight into the sharps container

Rotate the site each time so the tissue does not get irritated. Never the same spot twice in a row.

Because of the NAD+ share, inject especially slowly (NAD+ flush).

What the research shows

NAD+ is broadly studied (overview: Rajman, 2018), MOTS-c is also described in mitochondrial research. 5-Amino-1MQ comes from preclinical metabolic research. For the fixed triple combination in humans there are no controlled studies, the benefit derives from the individual compounds and is clearly experimental.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Weight and fat in obese mice4

Component 5-amino-1MQ alone, 11 days under the skin, change in percent

Body weight4 compared with baseline
Comparison group (no compound or placebo) +1.4%
5-Amino-1MQ alone (mice) -5.1%
Epididymal fat tissue4 Mass compared with the control group
Comparison group (no compound or placebo) 0.0%
5-Amino-1MQ alone (mice) -35.0%
Total blood cholesterol4 compared with the control group
Comparison group (no compound or placebo) 0.0%
5-Amino-1MQ alone (mice) -30.0%

Values from the results section of the full text (about 5.1 and 1.4 percent, about 35 and 30 percent). Food intake stayed the same. Measured with 5-amino-1MQ alone, not with the blend, not studied in humans.

Component NAD+ in heart failure7

180 adults, 7 days of NAD+ or placebo as an infusion, pump function after 1 month

Pump function (LVEF)7
Comparison group (no compound or placebo) 42.4%
NAD+ alone as an infusion (humans) 45.4%

Abstract values 45.44 and 42.44 percent. NAD+ was given into a vein here, not under the skin and not together with MOTS-c or 5-amino-1MQ.

Cross-section of glass fat tissue with large pale fat cells and small glowing orange mitochondria between them
Data exist only for the single components, mostly from animal studies. Symbolic image.

Research status

Where the research stands

There is no registered trial of the blend. Listed here are trials of single components: NAD+ as an injection or infusion and a modified form of MOTS-c. There are none for 5-amino-1MQ. As of 26 Oct 2026. 10

  1. Preclinical 5-Amino-1MQ only in cell assays and mice
  2. Phase 1 2 trials on components, 1 completed
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
No approval for the blend or any of its components. ChEMBL lists NAD+ without an approval year.4
Show all 1 trial on a timelineHide timeline 0 completed 1 running 0 with results
Without phase

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 2 trials on safety and pharmacokinetics, not shown as bars.

Side effects

  • Flush or pressure feeling during dosing (NAD+ part), especially when injecting too fast.
  • Local reactions at the injection site.
  • Solid data on the combination are missing.

Storage

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 4 to 6 months with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark

Robust, no fridge needed.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

At least 4 to 6 months with barely any loss of potency.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same targets or blends with NAD+ + MOTS-C + 5-Amino-1MQ Blend: all in the TPD lexicon.

NAD+ + MOTS-C + 5-Amino-1MQ Blend
NAD+ Component NAD+ alone, powder NAD+ IV Component NAD+ for infusion NAD+ Inject Component NAD+ as a ready solution MOTS-c Component MOTS-c alone 5-Amino-1MQ Component 5-amino-1MQ alone 5-Amino + NAD+ (Oral) Similar idea as a tablet

FAQ

Common questions about NAD+ + MOTS-C + 5-Amino-1MQ Blend

Short answers, each backed by the sources below.

Are there studies on this blend?

No. ClinicalTrials.gov lists no trial with this combination (as of 26 Oct 2026). What is known comes from studies on NAD+, MOTS-c and 5-amino-1MQ alone. Whether the three act differently together has not been studied.10

What do the three components do?

NAD+ is a coenzyme of energy production and fuel for enzymes such as the sirtuins. MOTS-c is a peptide of 16 amino acids from mitochondrial DNA, it inhibits the folate cycle and thereby activates AMPK. 5-Amino-1MQ inhibits the enzyme NNMT, in fat cells NAD+ and SAM rose with it.234

What did 5-amino-1MQ show in mice?

Obese mice lost about 5.1 percent of their weight in 11 days, while the control group gained 1.4 percent. Fat tissue was about 35 percent lighter and total cholesterol about 30 percent lower. Food intake stayed the same, the researchers saw no observable side effects. 5-Amino-1MQ has not been studied in humans.4

What is known about MOTS-c?

In mice MOTS-c prevented age-related insulin resistance, insulin resistance caused by a high-fat diet and obesity from a high-fat diet. Its main target appears to be skeletal muscle. A modified form called CB4211 was tested in a phase 1 trial with 88 participants, results are not posted in the registry.3510

What is known about NAD+ in humans?

NAD+ has been studied as an infusion. In a pilot study it vanished from the plasma at once for the first 2 hours. In 180 people with heart failure pump function after 7 days of infusion and 1 month was 45.4 against 42.4 percent on placebo. A review found no outcome study with NAD+ into a vein or muscle for ageing.679

Which side effects are known?

There are no data on the blend. As an infusion NAD+ led to gastrointestinal symptoms, a faster pulse and chest pressure in a clinic review, which ended with the infusion. With 5-amino-1MQ the researchers saw no observable side effects in mice, human data are missing.84

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

AMPK
Energy sensor of the cell. Activated when energy runs low, it switches to burning fuel and taking up sugar.
Coenzyme
Helper molecule that assists enzymes and is changed or consumed in the process.
Infusion
Slow delivery of a fluid directly into a vein, usually by drip.
Insulin resistance
A state in which cells respond less to insulin. Blood sugar then stays raised more easily.
Lyophilisate
Freeze-dried powder. Without water the compounds keep much longer.
Mitochondria
Power plants of the cell with their own small DNA. Their respiratory chain produces most of the energy carrier ATP.
Mitochondrial peptide
A short protein whose blueprint lies in mitochondrial DNA, not in the nucleus. MOTS-c is an example.
NNMT
Nicotinamide N-methyltransferase, an enzyme mainly in fat and liver. It uses up nicotinamide that would otherwise be available for NAD+.
Preclinical
Research before use in humans, in cell cultures and animal models.
Sirtuins
Family of seven enzymes (SIRT1 to 7) that consume NAD+ and control genes and metabolism.
Subcutaneous
Into the fat layer just under the skin.

Evidence

Sources

Show all 12 sourcesHide sources 9 Studies1 Trial registry2 Database checked 26 Oct 2026

Studies

  1. Review: NAD-boosting molecules in animal studies

    Rajman, Chwalek und Sinclair, Cell Metabolism, 2018

    DOI 10.1016/j.cmet.2018.02.011 PMID 29514064
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Review: NAD+ metabolism and ageing

    Covarrubias et al., Nature Reviews Molecular Cell Biology, 2021

    DOI 10.1038/s41580-020-00313-x PMID 33353981
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Discovery of MOTS-c, metabolism and insulin resistance (mice)

    Lee et al., Cell Metabolism, 2015

    DOI 10.1016/j.cmet.2015.02.009 PMID 25738459
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  4. NNMT inhibitor 5-amino-1MQ in obese mice

    Neelakantan et al., Biochemical Pharmacology, 2018

    DOI 10.1016/j.bcp.2017.11.007 PMID 29155147
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  5. Review naming CB4211 as a MOTS-c analogue in phase 1

    Sousa et al., Biomedicines, 2023

    DOI 10.3390/biomedicines11092331 PMID 37760774
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  6. Pilot study: NAD+ as a 6-hour infusion

    Grant et al., Frontiers in Aging Neuroscience, 2019

    DOI 10.3389/fnagi.2019.00257 PMID 31572171
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. NAD+ infusion in heart failure, randomised against placebo

    Yu et al., American Journal of Cardiovascular Drugs, 2026

    DOI 10.1007/s40256-025-00764-7 PMID 40954388
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  8. Tolerability of NAD+ and NR infusions in a clinic

    Reyna et al., Frontiers in Aging, 2026

    DOI 10.3389/fragi.2026.1652582 PMID 41704678
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  9. Systematic review: NAD+ for anti-ageing

    Gallagher und Emmanuel, Ageing Research Reviews, 2026

    DOI 10.1016/j.arr.2026.103057 PMID 41655607
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Search on ClinicalTrials.gov (no trial of the blend)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. NAD+ (nadide) in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL1234613)

    Checked 26 Oct 2026 via ChEMBL
  2. Target proteins in UniProt and ChEMBL

    UniProt und ChEMBL, EMBL-EBI (SIRT1, AMPK alpha-1, NNMT)

    Checked 26 Oct 2026 via UniProt, ChEMBL

In the shop

NAD+ + MOTS-C + 5-Amino-1MQ Blend in the catalog

Sizes, prices and shipping times are on the product page.

To the product